{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:15:21Z","timestamp":1779887721899,"version":"3.53.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T00:00:00Z","timestamp":1353628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s12185-012-1222-7","type":"journal-article","created":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T17:12:17Z","timestamp":1353604337000},"page":"135-138","source":"Crossref","is-referenced-by-count":34,"title":["Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin"],"prefix":"10.1007","volume":"97","author":[{"given":"Yoshikiyo","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,23]]},"reference":[{"key":"1222_CR1","doi-asserted-by":"crossref","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114: [abstract] 1126.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"1222_CR2","doi-asserted-by":"crossref","unstructured":"Saglio G, Larson RA, Hughes TP, Issaragrisil S, Turkina AG, Marin D, et al. Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (Pts) with type 2 diabetes in the ENESTnd trial. Blood 2010;116: [abstract] 3430.","DOI":"10.1182\/blood.V116.21.3430.3430"},{"key":"1222_CR3","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","volume":"18","author":"PW Manley","year":"2010","unstructured":"Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem. 2010;18:6977\u201386.","journal-title":"Bioorg Med Chem"},{"key":"1222_CR4","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542\u201351.","journal-title":"N Engl J Med"},{"key":"1222_CR5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428191003637282","volume":"51","author":"G Rosti","year":"2010","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, Baccarani M. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a \u2018head-to-head comparison\u2019. Leuk Lymphoma. 2010;51:583\u201391.","journal-title":"Leuk Lymphoma"},{"key":"1222_CR6","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009;114:4933\u20138.","journal-title":"Blood"},{"key":"1222_CR7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1222_CR8","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","volume":"31","author":"M Breccia","year":"2007","unstructured":"Breccia M, Muscaritoli M, Gentilini F, Latagliata R, Carmosino I, Rossi Fanelli F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007;31:1770\u20132.","journal-title":"Leuk Res"},{"key":"1222_CR9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"1222_CR10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","volume":"61","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441\u20136.","journal-title":"Cancer"},{"key":"1222_CR11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141\u20135.","journal-title":"Blood"},{"key":"1222_CR12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123\u20139.","journal-title":"Blood"},{"key":"1222_CR13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/asheducation-2011.1.121","volume":"2011","author":"CC Smith","year":"2011","unstructured":"Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011;2011:121\u20137.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1222_CR14","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","volume":"69","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69:999\u20131004.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1222_CR15","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","volume":"22","author":"M Breccia","year":"2004","unstructured":"Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph\u00a0+\u00a0chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol. 2004;22:4653\u20135.","journal-title":"J Clin Oncol"},{"key":"1222_CR16","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.leukres.2008.01.015","volume":"32","author":"M Breccia","year":"2008","unstructured":"Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, Alimena G. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008;32:1626\u20138.","journal-title":"Leuk Res"},{"key":"1222_CR17","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.leukres.2011.12.011","volume":"36","author":"M Breccia","year":"2012","unstructured":"Breccia M, Loglisci G, Salaroli A, Serrao A, Alimena G. Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. Leuk Res. 2012;36:e66\u20137.","journal-title":"Leuk Res"},{"key":"1222_CR18","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.leukres.2009.01.040","volume":"33","author":"M Breccia","year":"2009","unstructured":"Breccia M, Alimena G. The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism. Leuk Res. 2009;33:871\u20135.","journal-title":"Leuk Res"},{"key":"1222_CR19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1042\/CS20070122","volume":"114","author":"R Hagerkvist","year":"2008","unstructured":"Hagerkvist R, Jansson L, Welsh N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond). 2008;114:65\u201371.","journal-title":"Clin Sci (Lond)"},{"key":"1222_CR20","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","volume":"105","author":"C Louvet","year":"2008","unstructured":"Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008;105:18895\u2013900.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1222_CR21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev.immunol.26.021607.090320","volume":"26","author":"BA Sayed","year":"2008","unstructured":"Sayed BA, Christy A, Quirion MR, Brown MA. The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol. 2008;26:705\u201339.","journal-title":"Annu Rev Immunol"},{"key":"1222_CR22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejphar.2005.12.067","volume":"533","author":"L Reber","year":"2006","unstructured":"Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol. 2006;533:327\u201340.","journal-title":"Eur J Pharmacol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1222-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1222-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1222-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T15:25:37Z","timestamp":1594913137000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1222-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,23]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1222-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,23]]}}}